Not yet taking people in Spanyolország2. fázis
Evaluation of the regenerative efficacy of Endoret® (PRGF-Plasm Rich in Growth Factors) on the ocular surface of glaucoma patients treated chronically with ocular hypotensive drugs, Evaluación de la eficacia regenerativa de Endoret® (PRGF-Plasma Rico en Factores de Crecimiento) en la superficie ocular de pacientes glaucomatosos tratados de forma crónica con fármacos hipotensores oculares
Key facts
- Where
- Barcelona, SpanyolországSee the site
- Phase
- 2. fázis
Where in Spanyolország
- Hospital de la Santa Creu i Sant PauBarcelona, SpanyolországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
- Trial code
- EU 2025-520642-29-00
- Record updated
- 2025. január 29.
- Original description
To assess the changes in tear osmolarity after topical treatment with PRGF.Read full original descriptionShow less
To assess the changes in tear osmolarity after topical treatment with PRGF.
Inclusion: Adult patients diagnosed with glaucoma who are undergoing treatment with at least two ocular hypotensive drugs (3 drops/day) without preservatives for a minimum of the last two years and who consent to participate in the study.
Exclusion: Ocular surface pathology other than toxicity due to ocular hypotensive drugs; Previous ocular surface surgeries; Treatment with topical blood derivatives in the last 6 months; Allergy to local anesthetics; Women of childbearing age with pregnancy intention, pregnant women, and breastfeeding women.